Summary
Treatment of idiopathic pulmonary arterial hypertension (PAH) with the β-blocker bisoprolol resulted in decreased heart rate, increased right ventricular ejection fraction (RVEF), and improved quality of life. This article presents data from the Beta-Blocker Therapy in Idiopathic Pulmonary Arterial Hypertension trial [NCT01246037; Van Campen JSJA et al. Am J Respir Crit Care 2014].
- Thromboembolic Disease
- Pulmonary Clinical Trials
- Hypertensive Disease
- Pulmonary & Critical Care
- Thromboembolic Disease
- Pulmonary Clinical Trials
- Hypertensive Disease
- © 2014 MD Conference Express®
Tools
Table of contents
Cited By...
- No citing articles found.